Body distribution of camptothecin solid lipid nanoparticles after oral administration

Pharmaceutical Research

Volumn 16, Issue 5, 1999, Pages 751-757

  Yang, Shicheng ^a,b   Zhu, Jiabi ^b   Lu, Yu ^c   Liang, Bingwen ^c   Yang, Changzheng ^a  

^a NANJING UNIVERSITY   (China)

^b CHINA PHARMACEUTICAL UNIVERSITY   (China)

^c No 454 Hospital of PLA   (China)

Author keywords

Body distribution; Camptothecin; Drug targeting; Solid lipid nanoparticles; Sustained release

Indexed keywords

CAMPTOTHECIN; LIPID; NANOPARTICLE; POLOXAMER;

ANIMAL EXPERIMENT; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; BODY DISTRIBUTION; CONTROLLED STUDY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG RELEASE; DRUG STRUCTURE; DRUG TISSUE LEVEL; ELECTROPHORETIC MOBILITY; ENCAPSULATION; MEAN RESIDENCE TIME; MOUSE; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; REVERSED PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; SOLID; TRANSMISSION ELECTRON MICROSCOPY; ZETA POTENTIAL;

ADMINISTRATION, ORAL; ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; BLOOD-BRAIN BARRIER; CAMPTOTHECIN; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DELAYED-ACTION PREPARATIONS; MICE; MICE, INBRED C57BL; PARTICLE SIZE; TISSUE DISTRIBUTION;

EID: 0032909537     PISSN: 07248741     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1018888927852     Document Type: Article

References (30)

1. 1. R. H. Müller, W. Mehnert, J. S. Lucks, C. Schwarz, A. zur Mühlen, H. Weyhers, C. Freitas, and D. Rühl. Solid lipid nanoparticles (SLN)-An alternative colloidal carrier system for controlled drug delivery. Eur. J. Pharm. Biopharm. 41:62-69 (1995).
2. 2. C. Schwarz, W. Mehnert, J. S. Lucks, and R. H. Müller. Solid lipid nanoparticlcs (SLN) for controlled drug delivery. I. Production, characterization and sterilization. J. Contr. Rel. 30:83-96 (1994).
3. 3. B. Sickmann, and K. Westesen. Investigations on solid lipid nanoparticles prepared by precipitation in o/w emulsions. Eur. J. Pharm. Biopharm. 43:104-109 (1996).
4. 4. R. Cavalli, E. Marengo, L. Rodriguez, and M. R. Gasco. Effects of some experimental factors on the production process of solid lipid nanoparticles. Eur. J. Pharm. Biopharm. 43:110-115 (1996).
5. 5. R. H. Müller, D. Rühl, S. Runge, K. Schulze-Forster, and W. Mehnert. Cytotoxicity of solid lipid nanoparticles as a function of the lipid matrix and the surfactant. Pharm. Res. 14:458-462 (1997).
6. 6. J. Humberstone, and W. N. Charman. Lipid-based vehicles for the oral delivery of poorly water soluble drugs, Adv. Drug Deliv. Rev. 25:103-128 (1997).
7. 7. E. C. Lavelle, S. Sharf, N. W. Thomas, J. Holland, and S. S. Davis. The importance of gastrointestinal uptake of particles in the design of oral delivery systems. Adv. Drug Deliv. Rev. 18:5-22 (1995).
8. 8. C. Jaxel, K. W. Kohn, M. C. Wani, M. E. Wall, and Y. Pommier. Structure-activity study of the actions of camptothecin derivatives on mammalian topoisomerase I: Evidence for a specific receptor site and for a relation to antitumor activity. Cancer Res. 49:1465-1469 (1989).
9. 9. M. Potmesil. Camptothecins: from bench research to hospital wards. Cancer Res. 54:1431-1439 (1994).
10. 10. J.-P. Lon and A. E. Ahmed. Determination of camptothecin in biological fluids using reversed-phase high-performance liquid chromatography with fluorescence detection. J. Chromatogr. Biomed. Appl. 530:367-376 (1990).
11. 11. J. H. Beijnen. High-performance liquid chromatographic analysis of the antitumour drug camptothecin and its lactone ring-opened form in rat plasma. J. Chromatogr. Biomed. Appl. 617:111-117 (1993).
12. 12. J. Fassberg and V. J. Stella. A kinetic and mechanistic study of the hydrolysis of camptothecin and some analogues. J. Pharm. Sci. 81:676-684 (1992).
13. 13. T. G. Burke and Z. Mi. The structural basis of camptothecin interactions with human serum albumin impact on drug stability. J. Med. Chem. 37: 40-46 (1994).
14. 14. R. H. Müller, D. Rühl, and S. A. Runge. Biodegradation of solid lipid nanoparticles as a function of lipase incubation time. Int. J. Pharm. 144:115-121 (1996).
15. 15. R. Löbenberg, L. Araujo, and J. Kreuter. Body distribution of azidothymidine bound to nanoparticles after oral administration. Eur. J. Pharm. Biopharm. 44:127-132 (1997).
16. 16. C. M. Adeyeye and F. F. Chen. Stereoselective disposition of suspensions of conventional and wax-matrix sustained release ibuprofen microspheres in rats. Pharm. Res. 14:1811-1816 (1997).
17. 17. P. P. Constantinides, G. Welzel, H. Ellens, P. L. Smith, S. Sturgis, S. H. Yiv, and A. B. Owen. Water-in-oil microemulsions containing medium-chain fatty acids/salts: formulation and intestinal absorption enhancement evaluation. Pharm. Res. 13:210-215 (1996).
18. 18. P. Speiser. Lipidnanopellets als Trägersystem für Arzneimittel zur peroralen Anwendung. European Patent Application EP 0 167 825 (15.01.86).
19. 19. M. P. Desai, V. Labhasetwar, G. L. Amidon, and R. J. Levy. Gastrointestinal uptake of biodegradable microparticles: effect of particle size. Pharm. Res. 13:1838-1845 (1996).
20. 20. J. H. Eldridge, C. J. Hammond, J. A. Meulbroek, J. K. Staas, R. M. Gilley, and T. R. Tice. Controlled vaccine release in the gut-associated lymphoid tissues. I. Orally administered biodegradable microspheres target the Peyer's patches. J. Conr. Rel. 11:205-214 (1990).
21. 21. N. Hussain, P. U. Jani, and A. T. Florence. Enhanced oral uptake of tomato lectin-conjugated nanoparticles in the rat. Pharm. Res. 14:613-618 (1997).
22. 22. L. H. McMinn, G. M. Hodges, and K. E. Carr. Gastrointestinal uptake and translocation of microparticles in the streptozotocin-diabetic rat. J. Anat. 189:553-559 (1996).
23. 14C]poly (DL-lactide-co-glycolide) nanoparticles after intravenous and oral administration to mice. Int. J. Pharm. 106:201-211 (1994).
24. 24. P. Jani, W. Halbert, J. Langridge, and A. T. Florence. The uptake and translocation of latex nanoparticles and microparticles after oral administration to rats. J. Pharm. Pharmcol. 41:809-812 (1989).
25. 2 analogue. J. Pharm. Pharmacol. 48:1016-1022 (1996).
26. 26. J. Kreuter, R. N. Alyautdin, D. A. Kharkevich, and A. A. Ivanov. Passage of peptides through the blood-brain barrier with colloidal polymer particles (nanoparticles). Brain Res. 674:171-174 (1995).
27. 27. Z. Mi and T. G. Burke. Differential interactions of camptothecin lactone and carboxylated forms with human blood components. Biochemistry 33:10325-10336 (1994).
28. 28. J. Kreuter. Drug targeting with nanoparticles. Eur. J. Drug Metab. Pharmacokinet. 19:253-256 (1994).
29. 29. P. H. Beck, J. Kreuter, W. E. G. Müller, and W. Schatton. Improved peroral delivery of avarol with polybutylcyanoacrylate nanoparticles. Eur J. Pharm. Biopharm. 40:134-137 (1994).
30. 30. Y. I. Kim, L. Fluckiger, M. Hoffman, I. Lartaud-Idjouadiene, J. Atkinson, and P. Maincent. The antihypertensive effect of orally administered nifedipine-loaded nanoparticles in spontaneously hypertensive rats. Br. J. Pharmacol. 120:399-404 (1997).